Heart and liver fatty acid binding proteins and the metabolic syndrome Bert Binas OriginalPaper Pages: 401 - 406
Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation Karalyn D. CuthbertJason R. B. Dyck OriginalPaper Pages: 407 - 411
Role of hypertension in the metabolic syndrome: Who is affected? Gladys VelardeBradford C. Berk OriginalPaper Pages: 418 - 426
You are what you breathe: Evidence linking air pollution and blood pressure Robert D. Brook OriginalPaper Pages: 427 - 434
Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care Ann M. BorzeckiDan R. Berlowitz OriginalPaper Pages: 439 - 449
Hypertension in young children and neonates John Edward JonesPedro A. Jose OriginalPaper Pages: 454 - 460
Selection of antihypertensive agents in patients at risk for diabetes Susan Simmons Holcomb OriginalPaper Pages: 461 - 465
Antihypertensive agents for aging patients who are at risk for cognitive dysfunction Ihab HajjarMichelle KeownBrandy Frost OriginalPaper Pages: 466 - 473
Does ALLHAT change the management of hypertension in chronic kidney disease? Martin MacKinnonFrans H. H. LeenenMarcel Ruzicka OriginalPaper Pages: 474 - 483